- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ARIDIS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 20.12.24 | Aridis Pharmaceuticals, Inc.: Aridis Provides Corporate Update | 461 | GlobeNewswire (Europe) | LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) ("Aridis" or the "Company"), a biopharmaceutical company, today announced a corporate update on recent... ► Artikel lesen |
1 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 91,35 | +1,27 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| EVOTEC | 7,062 | +0,11 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| MODERNA | 23,695 | +0,32 % | Watch Cigna, Moderna, Reddit, and More | ||
| VALNEVA | 3,958 | -1,54 % | Valneva-Aktie rückt zum Wochenstart in den Mittelpunkt - Marktteilnehmer bleiben wachsam! | ||
| NOVAVAX | 7,239 | -0,75 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,040 | 0,00 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 31, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| INFLARX | 1,249 | -1,11 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,500 | +3,27 % | Coherus Oncology, Inc.: Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 | ||
| OCULAR THERAPEUTIX | 10,100 | -0,15 % | Ocular Therapeutix stock price target raised to $20 from $14 at TD Cowen | ||
| CYTOMX THERAPEUTICS | 3,156 | +1,74 % | CytomX Therapeutics Inc.: CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 | ||
| AC IMMUNE | 2,990 | +1,70 % | AC Immune SA: Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine | Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed Phase 1b/2a trial of ACI-35.030 and JACI-35.054... ► Artikel lesen | |
| CIDARA THERAPEUTICS | 92,50 | -2,12 % | Cidara Therapeutics, Inc.: Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention | SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,050 | -3,07 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update | PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero... ► Artikel lesen | |
| NEXTCURE | 12,480 | +3,70 % | NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States | First U.S. patient dosed at a mid-tier dose level where multiple responses have been observedMulti-regional trial to accelerate time to proof-of-concept data in 1H 2026 BELTSVILLE, Md. and SHANGHAI... ► Artikel lesen | |
| DIANTHUS THERAPEUTICS | 29,400 | -3,29 % | Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting |
ARIDIS PHARMACEUTICALS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARIDIS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.